Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) rises 43.3% from a year ago
Property, plant & equipment (net) stood at $861K at the end of Q1 FY2026, up 43.3% from a year earlier and up 394.8% from the prior quarter. Over 3 fiscal years it compounded at +0.0% a year.
Context
- Property, plant & equipment (net) amounted to 1.3% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Property, plant & equipment (net) increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps rising in the next quarterly balance sheet after a +43.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 174K USD
- Year-over-year change
- -75.8%
- 4-year CAGR
- -15.0%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 174K | -75.8% |
| FY2024 | 2024-12-31 | 720K | -9.1% |
| FY2023 | 2023-12-31 | 792K | +355.2% |
| FY2022 | 2022-12-31 | 174K | -47.7% |
| FY2021 | 2021-12-31 | 333K | — |
Property, Plant & Equipment (Net) vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +43.3% is the highest of 9, against a peer median of -54.5%.
- Property, plant & equipment (net) amounts to 1.3% of total assets for UNCY, versus a peer median of 2.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CBUSCibus, Inc. | Mar 2026 | $26.57M USD | -37.4% | +15.4% | 8.2% |
| Mar 2026 | $15.47M USD | -42.9% | -25.8% | 8.6% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $6.91M USD | -13.5% | +2.6% | 6.4% |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$4.08M CAD | -74.0% | +63.7% | 17.6% |
| Mar 2026 | $2.29M USD | -75.8% | — | 2.2% | |
| Mar 2026 | $983K USD | -36.2% | -13.8% | 0.5% | |
| Mar 2026 | $861K USD | +43.3% | +0.0% | 1.3% | |
| Mar 2026 | $486K USD | -66.2% | -63.0% | 0.5% | |
| Mar 2026 | $67K USD | -99.3% | -73.2% | 0.1% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding UNCY) | — | -54.5% | -13.8% | 2.2% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.